Rheumatoid Arthritis

Patent Granted For DNA Vaccine Technology

Published in Gene Therapy Weekly, April 19th, 2001

The Immune Response Corp. (IMNR) announced March 30, 2001, that it has received U.S. Patent Number 6,207,645 expanding coverage relating to its immune-based therapy for rheumatoid arthritis, Ravax^TM.

The recently issued patent has specific claims covering immunization using DNA vaccines that are designed to synthesize the T-cell receptor (TCR) V(beta) specific peptides in situ, in contrast to immunizing directly with the TCR peptides themselves. The patent also includes specific claims for DNA vaccines encoding key superantigen protein sequences from the V(beta) 3, V(beta) 14, and V(beta) 17 regions of the TCR present on the surface of these pathogenic T...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2001-04-19)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry